Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
- Single-center, prospective, active-controlled, open, randomized, 2 arm parallel,
interventional, exploratory pilot
- Type 2 diabetic patients with high cardiovascular risks who have inadequate glycaemic
control with metformin-based oral hypoglycemic agents will be prescribed glimepiride
(comparison group) or empagliflozin (study group) for 60 days (plus or minus 32 days) as
add-on therapy
- Changes in IL-1beta secretion, serum beta-hydroxybutyrate concentration, and NLRP3
inflammasome activity from baseline to final timepoint will be assessed.